We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nuvo Announces Notice of Intention to Grant a European Patent for PENNSAID® 2%
News

Nuvo Announces Notice of Intention to Grant a European Patent for PENNSAID® 2%

Nuvo Announces Notice of Intention to Grant a European Patent for PENNSAID® 2%
News

Nuvo Announces Notice of Intention to Grant a European Patent for PENNSAID® 2%

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nuvo Announces Notice of Intention to Grant a European Patent for PENNSAID® 2%"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nuvo Research Inc. has announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID® 2% product.

Upon grant by the European Patent Office, the patent can be officially validated in over 37 European countries.

PENNSAID 2% is protected by issued patents in the United States expiring April 21, 2028 and in New Zealand, South Africa and the Russian Federation with an expiration date of October 17, 2027.

Patent applications covering PENNSAID 2% are currently pending in Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan and Mexico and have an anticipated expiry date of October 17, 2027.

The Company is currently in discussions with potential marketing partners interested in licensing PENNSAID and/or PENNSAID 2% for Europe, Russia, China, the Middle East, Asia and Australia.

"We are very pleased with the progress we are making to secure worldwide patent protection for our next generation topical NSAID, PENNSAID 2%," said Tina Loucaides, Nuvo's Vice-President and General Counsel.

Loucaides continued, "This expanding patent portfolio supports our efforts to secure international licensing partners for PENNSAID 2% and additional sources of revenue for Nuvo."

Advertisement